In the ever-evolving world of healthcare and pharmaceuticals, researchers are constantly seeking ways to make drug development more efficient and effective. Sano’s new report, “Why are drug targets with genetic evidence twice as likely to succeed in trials?” sheds light on the use of genetic evidence to significantly increase the success rates of drugs in clinical trials, offering a glimpse into the future of personalised medicine.
The report discusses how advancements in genomics, molecular biology, data analytics, and machine learning have made it possible to pinpoint proteins associated with diseases. It highlights real-world case studies that showcase the effectiveness of this approach, from oncology to cardiovascular disease, but also discusses the challenges and limitations that come with genetic evidence. Ultimately, this report offers a glimpse into a future where drug development is more tailored, efficient, and patient-centric.